Skip to main content

The Basel-based pharmaceutical company Myovant Sciences has published positive study results for its therapy relugolix, which has now been shown to be effective and safe for the treatment of uterine fibroids.

The Phase 3 study compared relugolix with leuprorelin for the treatment of uterine fibroids in Japanese women. Uterine fibroids result in debilitating heavy menstrual bleeding and anaemia. Proper treatment can reduce menstrual bleeding.

“The positive results of decreased menstrual bleeding from Takeda’s Phase 3 study of relugolix in Japanese women with uterine fibroids provides strong support for Myovant’s ongoing Phase 3 studies with relugolix in North America, Europe and other regions,” Lynn Seely, CEO of Myovant Sciences, said in a statement.

Uterine fibroids oftentimes require a hysterectomy to control the bleeding, added Seely. Myovant Sciences is working to develop relugolix, an oral, once-daily medication, to provide women an alternative to major surgery.

Myovant Sciences is a subsidiary of Roivant Sciences, which was assisted by in relocating its headquarters to Basel.

Myovant Sciences presented positive study results for other relugolix applications in recent months. For instance, patients with endometriosis and those with prostrate cancer have been successfully treated with the drug. It lowers oestrogen levels in women and testosterone levels in men.

Share this article

View all news

Sign up to receive our newsletter in your inbox.